SoInAb™
Antibody Discovery Platform
SoInAb™
Antibody Discovery Platform
Computational Power-Driven Discovery.
Faster, More Precise Antibody Discovery.
Integrating deep learning with multi-scale biophysical simulations, the platform enables de novo generation of high-activity antibodies directly from antigen epitopes, addressing undruggable targets and navigating patent landscapes.
The discovery cycle is reduced from 2–3 years to 6–12 months, with R&D costs lowered by 70%, while supporting predictive analysis for novel targets with no prior data.
-
Precise Generation
Directly designs antibody sequences against target epitopes, bypassing immunization or library screening. -
Efficiency Leap
Shortens R&D timelines to 6–12 months with a 70% cost reduction. -
Intelligent Screening
Employs physical simulations to predict binding efficacy, filtering out invalid candidates early. -
Breaking Bottlenecks
Addressing complex, traditionally undruggable targets, including GPCRs and ion channels. -
End-to-End Closed Loop
Fully automated workflow from sequence design to experimental validation, supporting rapid iteration. -
Global Rights
AI-generated novel sequences supporting differentiated sequence design and intellectual property positioning.
SoInAb™
Antibody Discovery Platform
SoInAb™
Antibody Discovery Platform
Computational Power-Driven Discovery.
Faster, More Precise Antibody Discovery.
Integrating deep learning with multi-scale biophysical simulations, the platform enables de novo generation of high-activity antibodies directly from antigen epitopes, addressing undruggable targets and navigating patent landscapes.
The discovery cycle is reduced from 2–3 years to 6–12 months, with R&D costs lowered by 70%, while supporting predictive analysis for novel targets with no prior data.
-
Precise Generation
Directly designs antibody sequences against target epitopes, bypassing immunization or library screening. -
Efficiency Leap
Shortens R&D timelines to 6–12 months with a 70% cost reduction. -
Intelligent Screening
Employs physical simulations to predict binding efficacy, filtering out invalid candidates early. -
Breaking Bottlenecks
Addressing complex, traditionally undruggable targets, including GPCRs and ion channels. -
End-to-End Closed Loop
Fully automated workflow from sequence design to experimental validation, supporting rapid iteration. -
Global Rights
AI-generated novel sequences supporting differentiated sequence design and intellectual property positioning.
Next-Generation Innovative Biologics Pipeline
Next-Generation
Innovative Biologics Pipeline
Candidate |
Indication |
Drug Design & Screening |
CMC/IIT |
IND |
Phase I/II/III |
NDA |
Commercial Rights |
|---|---|---|---|---|---|---|---|
| Metabolic Disease > | |||||||
| SunRay101Key Component | | Obesity, Sarcopenia, Heart Failure |
|
 |
||||
| SunRay102Key Component | | Obesity |
|
|
||||
| Neurodegenerative Disease > | |||||||
| SunRay201Key Component | | CNS Diseases (Delivery Vehicle) |
|
|
||||
| SunRay202Key Component | | Alzheimer's Disease |
|
|
||||
| SunRay203Key Component | | Alzheimer's Disease |
|
|
||||
| Musculoskeletal Disorders > | |||||||
| SunRay301Key Component | | Osteoarthritis Pain |
|
|
||||
SUNRAY R&D Pipeline
SUNRAY R&D Pipeline
Metabolic Disease
-
SunRay101
Investigational Antibody for Musculoskeletal Disorders
Focusing on skeletal muscle function maintenance and tissue homeostasis regulation, aiming to explore the potential to improve muscle health and motor function.
Mechanism of Action
Rational design balances molecular activity and selectivity.
Unmet Need
Addressing unmet clinical needs in musculoskeletal disorders, with the potential to help patients maintain muscle function and daily activities.
Current Status
Currently in preclinical research, with in vitro and in vivo studies underway.
-
SunRay102
Investigational Antibody for Metabolic Disorders
Focusing on obesity and metabolic-related conditions, exploring a differentiated mechanism for weight management with safety, durability, and comprehensive benefits.
Mechanism of Action
Based on the proprietary antibody discovery platform, investigational molecules with synergistic potential are being developed.
Unmet Need
Addressing the long-term management needs of patients with chronic metabolic conditions, exploring potential solutions to support metabolic health and quality of life.
Current Status
Molecular optimization and functional validation are underway.
Neurodegenerative Disease
-
SunRay201
CNS Delivery Platform
Addressing the challenge of brain delivery for biologics, a delivery technology system is being established to provide foundational support for drug development in neurological disorders.
Mechanism of Action
Aiming to explore the potential to enhance brain delivery efficiency and compatibility of macromolecular drugs.
Unmet Need
Exploring the potential to support the application of multiple biologics in CNS disorders.
Current Status
The platform is undergoing delivery performance testing, with preclinical validation underway.
-
SunRay202
Investigational Antibody for Neurodegenerative Diseases
Focusing on key pathological processes in neurodegenerative diseases, advancing the development of next-generation neurological therapies.
Mechanism of Action
Molecular design targeting disease initiation and progression mechanisms.
Unmet Need
Seeking therapeutic strategies with disease-modifying potential to address long-term clinical needs.
Current Status
Candidate molecule screening and preclinical evaluation are underway.
-
SunRay203
Investigational Antibody for Alzheimer's Disease
Focusing on Alzheimer's disease and other major brain disorders, aiming to explore the potential to slow disease progression and develop a next-generation therapeutic option.
Mechanism of Action
Molecular construction targeting characteristic pathological pathways of Alzheimer's disease, continuously enhancing overall development potential.
Unmet Need
Addressing the need for early intervention and full-course treatment, exploring more precise and effective potential strategies.
Current Status
Lead molecule evaluation and druggability studies are underway
Musculoskeletal Disorders
-
SunRay301
Investigational Antibody for Chronic Pain
Focusing on chronic pain, exploring the potential of a non-opioid analgesic approach, with attention to safety, precision, and long-term use requirements.
Mechanism of Action
Targeting upstream pathways in pain transmission, aiming to explore the potential effects of analgesic treatment.
Unmet Need
Addressing the limitations of existing pain management options, exploring potentially safer alternatives.
Current Status
Molecular iteration and indication strategy are progressing as planned.